Iron Mountain Tops Q3 2026 Estimates as Revenue Rises 14% to $1.991B
Revenue of $1.991B vs. $1.992B expected and adjusted EPS of $0.64 vs. $0.61; revenue up 14% from a year earlier.
Iron Mountain (IRM) topped estimates for the third quarter of 2026. Revenue was $1.991 billion, up 14% from a year earlier, in line with the $1.992 billion estimate, and adjusted EPS was $0.64, up 19% from a year earlier, above the $0.61 estimate.
Shares fell 1.0% in premarket trading as of 6:45 a.m. ET, to $117.58 from a $118.81 close.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | $0.61 | $0.64 | Beat by 4.6% |
| Revenue | $1.992B | $1.991B | In line |
| Change | YoY | QoQ |
|---|---|---|
| Adjusted EPS | ▲ 19% | ▲ 6.7% |
| Revenue | ▲ 14% | ▼ 1.9% |
By our calculation, adjusted EPS was $0.03 above it. The QoQ column compares with the previous quarter's revenue of $2.029 billion and adjusted EPS of $0.60. The YoY column compares with $1.754 billion and $0.54 in the same quarter a year earlier.
Track record
- EPS record. Adjusted EPS beat the estimate in 5 of the last 8 reports, including this one.
- Revenue record. Revenue beat the estimate in 4 of the last 8 reports.
- Revenue trend. Revenue over the last 5 reports, oldest first: $1.754 billion, $1.843 billion, $1.936 billion, $2.029 billion and $1.991 billion.
What to watch
- Next-quarter estimates. Consensus calls for EPS of $0.68 and revenue of $2.05 billion next quarter, based on 3 analysts.
- Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 14% increase to $1.991 billion.
- Estimate record. Whether Iron Mountain extends a record of beating EPS estimates in 5 of its last 8 reports.
- Related coverage. See our reports on Tapestry, Cardinal Health, Zai Lab and BeOne Medicines.
Sources: Results are from Iron Mountain's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Iron Mountain's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
Tapestry Beats Fiscal Q1 2027 Estimates as Revenue Rises 11% to $1.89B
EarningsCardinal Health Beats Fiscal Q1 2027 Estimates as Revenue Rises 5.5% to $67.51B
EarningsZai Lab Beats Q3 2026 Estimates as Revenue Falls 6.8% to $108.2M
EarningsBeOne Medicines Beats Q3 2026 Estimates as Revenue Rises 34% to $1.89B
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.